Stock Track | Ionis Pharmaceuticals Soars on Positive Angelman Syndrome Drug Update, Q3 Results

Stock Track11-06

Shares of Ionis Pharmaceuticals (IONS) soared 5.35% in pre-market trading on November 6, 2024, following a promising update on its investigational drug ION582 for treating Angelman syndrome and better-than-expected third quarter financial results.

Ionis announced that it has completed a positive End-of-Phase 2 discussion with the U.S. Food and Drug Administration (FDA) and received alignment on the design of the pivotal Phase 3 trial for ION582. The Phase 3 REVEAL trial will evaluate ION582 in approximately 200 children and adults with Angelman syndrome and use improvement in expressive communication as the primary endpoint.

Separately, Ionis reported total revenue of $134 million for the third quarter of 2024, beating the consensus estimate of $130.1 million. Revenue was driven by royalties from SPINRAZA and WAINUA, as well as collaborative agreement revenue. However, the company reported a net loss of $140 million or $0.95 per share for the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188140786?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188140786","market":"us","top_or_hot":-1,"title":"Stock Track | Ionis Pharmaceuticals Soars on Positive Angelman Syndrome Drug Update, Q3 Results","media":"Stock Track","content":"<p>Shares of Ionis Pharmaceuticals (IONS) soared 5.35% in pre-market trading on November 6, 2024, following a promising update on its investigational drug ION582 for treating Angelman syndrome and better-than-expected third quarter financial results.</p>\n\n<p>Ionis announced that it has completed a positive End-of-Phase 2 discussion with the U.S. Food and Drug Administration (FDA) and received alignment on the design of the pivotal Phase 3 trial for ION582. The Phase 3 REVEAL trial will evaluate ION582 in approximately 200 children and adults with Angelman syndrome and use improvement in expressive communication as the primary endpoint.</p>\n\n<p>Separately, Ionis reported total revenue of $134 million for the third quarter of 2024, beating the consensus estimate of $130.1 million. Revenue was driven by royalties from SPINRAZA and WAINUA, as well as collaborative agreement revenue. However, the company reported a net loss of $140 million or $0.95 per share for the quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ionis Pharmaceuticals Soars on Positive Angelman Syndrome Drug Update, Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ionis Pharmaceuticals Soars on Positive Angelman Syndrome Drug Update, Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 21:44 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Ionis Pharmaceuticals (IONS) soared 5.35% in pre-market trading on November 6, 2024, following a promising update on its investigational drug ION582 for treating Angelman syndrome and better...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IONS","symbol_name":"Ionis Pharmaceuticals, Inc","start_time":0,"source_url":"","article_id":"1188140786","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188140786","pubTimestamp":1730900691,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ionis Pharmaceuticals  soared 5.35% in pre-market trading on November 6, 2024, following a promising update on its investigational drug ION582 for treating Angelman syndrome and better-than-expected third quarter financial results.Ionis announced that it has completed a positive End-of-Phase 2 discussion with the U.S. Food and Drug Administration  and received alignment on the design of the pivotal Phase 3 trial for ION582. The Phase 3 REVEAL trial will evaluate ION582 in approximately","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"股票轨迹Ionis Pharmaceuticals因安格尔曼综合症药物更新和第三季度业绩积极而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":1},"content_text":"Shares of Ionis Pharmaceuticals (IONS) soared 5.35% in pre-market trading on November 6, 2024, following a promising update on its investigational drug ION582 for treating Angelman syndrome and better-than-expected third quarter financial results.\nIonis announced that it has completed a positive End-of-Phase 2 discussion with the U.S. Food and Drug Administration (FDA) and received alignment on the design of the pivotal Phase 3 trial for ION582. The Phase 3 REVEAL trial will evaluate ION582 in approximately 200 children and adults with Angelman syndrome and use improvement in expressive communication as the primary endpoint.\nSeparately, Ionis reported total revenue of $134 million for the third quarter of 2024, beating the consensus estimate of $130.1 million. Revenue was driven by royalties from SPINRAZA and WAINUA, as well as collaborative agreement revenue. However, the company reported a net loss of $140 million or $0.95 per share for the quarter.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188140786"}